UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

The lancet oncology, 2013-05, Vol.14 (6), p.552-562

2013

Link zum Volltext

Verfügbarkeit prüfen

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

The Lancet (British edition), 2011-12, Vol.378 (9807), p.1931-1939

2011

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

The lancet oncology, 2009-08, Vol.10 (8), p.757-763

2009

Link zum Volltext

Verfügbarkeit prüfen

Axitinib for the Management of Metastatic Renal Cell Carcinoma

Drugs in R&D, 2011-06, Vol.11 (2), p.113-126

2011

Link zum Volltext

Verfügbarkeit prüfen

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations

Journal of clinical oncology, 2008-12, Vol.26 (34), p.5530-5536

2008

Link zum Volltext

Verfügbarkeit prüfen

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

JNCI : Journal of the National Cancer Institute, 2011-05, Vol.103 (9), p.763-773

2011

Link zum Volltext

Verfügbarkeit prüfen

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

The New England journal of medicine, 2012-03, Vol.366 (10), p.883-892

2012

Link zum Volltext

Verfügbarkeit prüfen

Germline RAD51C mutations confer susceptibility to ovarian cancer

Nature genetics, 2012-05, Vol.44 (5), p.475-476

2012

Link zum Volltext

Verfügbarkeit prüfen

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Cancer research (Chicago, Ill.), 2016-05, Vol.76 (9), p.2778-2790

2016

Link zum Volltext

Verfügbarkeit prüfen

Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models

The Journal of pathology, 2017-02, Vol.241 (3), p.362-374

2017

Link zum Volltext

Verfügbarkeit prüfen

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Journal of clinical oncology, 2009-07, Vol.27 (20), p.3312-3318

2009

Link zum Volltext

Verfügbarkeit prüfen

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

JAMA : the journal of the American Medical Association, 2012-01, Vol.307 (4), p.382

2012

Link zum Volltext

Verfügbarkeit prüfen

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

Journal of clinical oncology, 2001-07, Vol.19 (14), p.3312-3322

2001

Link zum Volltext

Verfügbarkeit prüfen

Sunitinib in the treatment of metastatic renal cell carcinoma

Therapeutic Advances in Urology, 2016-12, Vol.8 (6), p.348-371

2016

Link zum Volltext

Verfügbarkeit prüfen

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma

Cancer discovery, 2013-02, Vol.3 (2), p.158-167

2013

Link zum Volltext

Verfügbarkeit prüfen

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

International journal of cancer, 2010-11, Vol.127 (9), p.2209-2221

2010

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

Journal of clinical oncology, 2011-10, Vol.29 (28), p.3798-3804

2011

Link zum Volltext

Verfügbarkeit prüfen

Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers

European urology, 2014-11, Vol.66 (5), p.936-948

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

European urology, 2016-02, Vol.69 (2), p.345-351

2016

Link zum Volltext

Verfügbarkeit prüfen

Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis

Journal of hepatology, 2021-07, Vol.75 (1), p.177-189

2021

Link zum Volltext

Verfügbarkeit prüfen

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Cancer Immunology, Immunotherapy, 2014-05, Vol.63 (5), p.449-458

2014

Link zum Volltext

Verfügbarkeit prüfen

The Future of Targeted Therapies in Ovarian Cancer

The oncologist (Dayton, Ohio), 2009-07, Vol.14 (7), p.706-716

2009

Link zum Volltext

Verfügbarkeit prüfen

The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole

BMC cancer, 2017-06, Vol.17 (1), p.456-456, Article 456

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 653

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(590)
Mit Volltextzugriff
(601)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(418)
Life Sciences & Biomedicine
(402)
Humans
(372)
Female
(234)
Male
(178)
Oncology
(176)
Adult
(160)
Middle Aged
(157)
Biological And Medical Sciences
(129)
Aged
(126)
Medical Sciences
(115)
Tumors
(69)
Treatment Outcome
(68)
Antineoplastic Agents - Therapeutic Use
(57)
Disease-Free Survival
(49)
Aged, 80 And Over
(47)
Ovarian Neoplasms - Drug Therapy
(47)
Pharmacology. Drug Treatments
(47)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(41)
Carcinoma, Renal Cell - Drug Therapy
(41)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Axitinib for the Management of Metastatic Renal Cell Carcinoma

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Germline RAD51C mutations confer susceptibility to ovarian cancer

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

Sunitinib in the treatment of metastatic renal cell carcinoma

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers

Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

The Future of Targeted Therapies in Ovarian Cancer

The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole

Suchergebnisse filtern